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                                  Gastric cancer is one of the most devastating human cancers, with 
approximately 880  000 new cases and 650  000 deaths worldwide 
per year (  1  ,  2  ). There are two types of gastric cancer: diffuse type 
and intestinal type. Diffuse-type gastric carcinoma, according to 
the Laurén classification (  3  ), is highly metastatic and characterized 
clinically by rapid disease progression and poor prognosis (  4  ). 
Although the incidence of intestinal-type gastric carcinoma has 
continuously decreased, the incidence of diffuse-type gastric carci-
noma has increased progressively during the last 30 years, so that 
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     Background     Diffuse-type gastric carcinoma is a cancer with poor prognosis that has high levels of transforming growth 
factor      (TGF-    ) expression and thick stromal fibrosis. However, the association of TGF-     signaling with 
diffuse-type gastric carcinoma has not been investigated in detail.         
     Methods     We used a lentiviral infection system to express a dominant-negative TGF-     type II receptor (dnT    RII) or 
green fluorescent protein (GFP) as a control in the diffuse-type gastric carcinoma cell lines, OCUM-2MLN and 
OCUM-12. These infected cells and the corresponding parental control cells were subcutaneously or orthoto-
pically injected into nude mice. Angiogenesis was inhibited by infecting cells with a lentivirus carrying the 
gene for angiogenic inhibitor thrombospondin-1 or by injecting mice intraperitoneally with the small-molecule 
angiogenic inhibitor sorafenib or with anti-vascular endothelial growth factor (VEGF) neutralizing antibody 
(six or eight mice per group). Expression of phospho-Smad2 and thrombospondin-1 was investigated immu-
nologically in human gastric carcinoma tissues from 102 patients. All statistical tests were two-sided.   
     Results     Expression of dnT    RII into OCUM-2MLN cells did not affect their proliferation in vitro, but it accelerated the 
growth of subcutaneously or orthotopically transplanted tumors in vivo (eg, for mean volume of subcutane-
ous tumors on day 10 relative to that on day 0: dnT    RII tumors = 3.49 and GFP tumors = 2.46, difference = 
1.02, 95% confidence interval [CI] = 0.21 to 1.84;   P   = .003). The tumors expressing dnT    RII had higher levels 
of angiogenesis than those expressing GFP because of decreased thrombospondin-1 production. Similar 
results were obtained with OCUM-12 cells. Expression of thrombospondin-1 in the dnT    RII tumor or treat-
ment with sorafenib or anti-VEGF antibody reduced tumor growth, whereas knockdown of thrombospon-
din-1 expression resulted in more accelerated growth of OCUM-2MLN tumors than of GFP tumors (eg, mean 
tumor volumes on day 14 relative to those on day 0: thrombospondin-1  –  knockdown tumors = 4.91 and GFP 
tumors = 3.79, difference = 1.12, 95% CI = 0.80 to 1.44;   P   < .001). Positive association between phosphory-
lated Smad2 and thrombospondin-1 immunostaining was observed in human gastric carcinoma tissues.   
     Conclusions     Disruption of TGF-     signaling in diffuse-type gastric carcinoma models appeared to accelerate tumor 
growth, apparently through increased tumor angiogenesis that was induced by decreased expression of 
thrombospondin-1.   
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the diffuse type constitutes approximately one-third of all gastric 
carcinomas diagnosed in the United States (  5  ). In contrast to the 
intestinal type, infection with   Helicobacter pylori   and chronic gastri-
tis are often absent in the diffuse-type gastric carcinoma. Patients 
with diffuse-type gastric carcinoma often have thick stromal fibro-
sis with undifferentiated carcinoma cells scattered in the intersti-
tium, which results in a stiff and thick gastric wall with reduced 
motility, but the tumors do not form ulcers or apparent mass 
lesions. 
  Transforming growth factor      (TGF-    ) is a multifunctional 
cytokine that contributes to cancer progression by acting in both 
tumor cells and the tumor stroma (  6  ). TGF-     binds to TGF-     
serine  –  threonine kinase receptors type I and type II (T    RII) and 
transduces signals by phosphorylation of the receptor-regulated 
Smad2 and Smad3 proteins. Smad2 and Smad3 form complexes 
with Smad4, and these complexes regulate transcription of various 
target genes in the nucleus (  7  ,  8  ). 
  Because TGF-     is a potent inhibitor of epithelial cell prolifera-
tion, resistance to the inhibitory activity of TGF-     results in 
increased cell proliferation and cancer progression (  9  ). Cancer 
cells in advanced tumors are often refractory to TGF-      –  induced 
growth inhibition, and some tumors even increase their produc-
tion of TGF-     ligands. TGF-     induces deposition of extracellular 
matrix in the tumor interstitium, which leads to ﬁ  brosis. TGF-     
also induces perturbations of immune surveillance and regulates 
angiogenesis in vivo. Moreover, TGF-     may promote tumor 
growth by inducing epithelial cells to undergo the epithelial  –
  mesenchymal transition (  10  ,  11  ), and inhibition of TGF-     signal-
ing has been reported to prevent progression and metastasis of 
certain advanced tumors (  12    –    15  ). In addition, decreased expression 
of T    RII, Smad2, and/or Smad4 or  loss-of-function mutations in 
at least one of these genes has been observed in advanced stages of 
certain cancers, including colorectal cancer, breast cancer, and 
prostate cancer (  16  ), and these changes in TGF-     signaling may 
affect progression of these cancers. 
  There is limited information regarding the role of TGF-     in 
diffuse-type gastric cancers. The thick stromal ﬁ  brosis observed 
in diffuse-type gastric carcinoma is induced by the TGF-     pro-
duced by cancer cells and by cancer-associated ﬁ  broblasts (  17  ). 
Production of TGF-    1 has been reported to be associated with 
the progression of diffuse-type gastric carcinoma (  18  ), although 
the relation of TGF-    1 expression to prognosis of gastric carci-
noma is controversial (  19  ). Disruption of TGF-     signaling by 
loss of Smad4 expression has also been observed in diffuse-type 
gastric carcinoma (  20  ). However, detailed investigations on 
the roles of TGF-     signaling in diffuse-type gastric carcinoma 
have not been carried out. We therefore investigated the role 
of TGF-     signaling in diffuse-type gastric carcinoma by use of 
OCUM-2MLN and OCUM-12 cell lines and by disrupting 
TGF-     signaling. 
    Patients, Materials, and Methods 
    Cell Lines 
  The OCUM-2MLN cell line was obtained from a lymph node 
metastasis of a mouse with orthotopically implantated OCUM-2M 
cells (  21  ); the OCUM-2M line was originally established from a 
49-year-old woman with diffuse-type gastric carcinoma (  4  ). The 
OCUM-12 cell line was established from the peritoneal effusion of 
a 58-year-old man with diffuse-type gastric carcinoma that was 
diagnosed by endoscopy and histology. OCUM-12 cells were 
further confirmed to be tumorigenic in nude mice [(  22  ) and 
M. Yashiro and K. Hirakawa, Osaka City University, unpublished 
data      ]. Both cell lines were cultured in Dulbecco  ’  s modified Eagle 
medium (DMEM) containing 10% fetal bovine serum, penicillin 
(100 U/mL), and streptomycin (0.1 mg/mL) (Invitrogen, Carlsbad, 
CA). To disrupt TGF-     signaling, we introduced a dominant-
negative TGF-     type II receptor (dnT    RII) that lacks the intrac-
ellular kinase domain into the OCUM-2MLN and OCUM-12 cell 
lines (resulting in the 2MLN-dnT    RII and OCUM-12-dnT    RII 
cell lines, respectively) by use of a lentiviral infection system (  23  ). 
We used the same lentivirus system to generate control OCUM-
2MLN and OCUM-12 cells that expressed green fluorescent 
protein (GFP) (resulting in the 2MLN-GFP and OCUM-12-GFP 
cell lines, respectively) and OCUM-2MLN cells that expressed 
both dnT    RII and the angiogenic inhibitor thrombospondin-1 
(resulting in the 2MLN-dnT    RII+TSP-1) (  24  ,  25  ). cDNAs for 
dnT    RII or for thrombospondin-1 were produced from mRNA 
extracted from the cultured OCUM-2MLN cell line by poly-
merase chain reaction (PCR). cDNAs encoding either dnT    RII 
with a carboxyl-terminal hemagglutinin epitope tag or thrombos-
pondin-1 were inserted into the multicloning site of the lentiviral 
    CONTEXT AND CAVEATS 
    Prior knowledge 
  Diffuse-type gastric carcinoma has poor prognosis. Patients have 
high levels of transforming growth factor      (TGF-    ) expression and 
thick stromal fibrosis.         
    Study design 
  The roles of TGF-     and thrombospondin-1, an angiogenic inhibitor 
that is regulated by TGF-    , were investigated in vitro studies in 
diffuse-type gastric carcinoma cell lines and in vivo studies in 
mouse models of diffuse-type gastric carcinoma and human 
diffuse-type gastric carcinoma tissue specimens from 102 patients.   
    Contribution 
  Growth of diffuse-type gastric carcinomas appeared to be acceler-
ated by disruption of TGF-     signaling in mouse models (which may 
be analogous to what occurs during progression of this disease in 
humans), apparently because of increased tumor angiogenesis 
that was induced by decreased expression of thrombospondin-1.   
    Implications 
  Because loss of a receptor for TGF-     has been reported to induce 
tumor angiogenesis in various cancers, administration of angio-
genesis inhibitors, such as sorafenib or thrombospondin-1 ana-
logues, should be investigated as a treatment for cancers with 
disrupted TGF-     signaling pathways.   
    Limitations 
  Although mouse models of subcutaneous and orthotopic trans-
plantation models were used, the experiments were conducted 
with immunocompromised mice. The growth of metastatic tumors 
was not investigated. 
    From the Editors       
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vector pCSII-CMV-RfA by use of pENTR, according to the 
manufacturer’s protocol (Invitrogen).   
    Antibodies and Reagents 
  The rabbit polyclonal antibodies against human and mouse phos-
phorylated Smad2 that were used for immunoblotting were a gift 
from A. Moustakas and C.-H. Heldin (Ludwig Institute for Cancer 
Research, Uppsala, Sweden). The rabbit monoclonal antibody 
against human and mouse phosphorylated Smad2 that was used for 
immunohistochemistry was from Millipore (Temecula, CA; clone 
A5S). The rat monoclonal antibody against mouse platelet  – 
endothelial cell adhesion molecule-1 (PECAM-1) and mouse 
monoclonal antibody against human and mouse Smad2 and Smad3 
(clone 18) were from BD (Franklin Lakes, NJ). The rat monoclo-
nal antibody against hemagglutinin tag (clone 3F10) was from 
Roche (Basel, Swiss), and mouse monoclonal antibody against 
GFP (clone 1E4) was from Medical & Biological Laboratories, Co. 
(Woburn, MA). Mouse monoclonal antibody against human and 
mouse thrombospondin-1 was from Abcam (Cambridge, UK; 
clone A6.1). Alexa 488  –   and Alexa 594  –  conjugated secondary anti-
bodies and the nuclear stain TOTO-3 for counterstaining were 
from Invitrogen Molecular Probes (Eugene, OR). TGF-    3 and 
TGF-    1, which show similar biological activities in vitro, were 
purchased from R&D Systems (Minneapolis, MN).   
    Immunoblot Analysis 
  We examined the expression of Smad2 and Smad3, phosphory-
lated Smad2, GFP, and hemagglutinin-tagged dnT    RII by 
immunoblot analyses in following cultured cells: 2MLN, 
2MLN-GFP, 2MLN-dnT    RII, OCUM-12, OCUM-12-GFP, 
and OCUM-12-dnT    RII. These cells were lysed in a buffer 
containing 50 mM Tris  –  HCl (pH 8.0), 150 mM NaCl, 1% 
Nonidet P-40 (Nacalai Tesque, Kyoto, Japan), 5 mM EDTA, 
0.5% deoxycholic acid sodium salt-monohydrate (Nacalai 
Tesque), 0.1% sodium dodecyl sulfate (SDS) (Nacalai Tesque), 
1% aprotinin (Mitsubishi Pharma, Osaka, Japan), and 1 mM 
phenylmethylsulfonyl fluoride (Sigma, St Louis, MO). The cell 
lysates were boiled in SDS sample buffer (100 mM Tris  –  HCl at 
pH 8.8, 0.01% bromophenol blue, 36% glycerol, 4% SDS, and 
10 mM dithiothreitol) and subjected to SDS  –  polyacrylamide gel 
electrophoresis. Proteins were electrotransferred from a poly-
acrylamide gel to Pall Fluorotrans-W membranes (Pall, East 
Hills, NY) and immunoblotted with antibodies. Bound antibod-
ies were detected by use of an enhanced chemiluminescence 
detection system (Amersham Pharmacia Biotech, Piscataway, 
NJ). Each experiment was conducted two times, and a represen-
tative result is shown.   
    Cell Proliferation Assay 
  We cultured 2.5 × 10  4   2MLN, 2MLN-GFP, 2MLN-dnT    RII, or 
OCUM-12 cells per well in 12-well plates. On the next day (des-
ignated as day 0), some cultures were treated with TGF-     and 
control cultures were left untreated. Cells from duplicate cultures 
were counted as indicated with a hemocytometer. Each experiment 
was conducted two times, sample points were assayed in triplicate, 
and data were averaged. Data from one representative experiment 
of these are shown.   
    BALB/c Nude Mouse Model for Human Gastric Cancer 
  BALB/c nude male mice, aged 4  –  5 weeks, were obtained from 
Oriental Yeast Co. (Tokyo, Japan). All animal experimental proto-
cols were performed in accordance with the policies of the Animal 
Ethics Committee of the University of Tokyo. A total of 5 × 10  6   
cells in 100   µ  L of DMEM (n > 6 mice per group) was injected 
subcutaneously at the left flank of each mouse and allowed to grow 
for 1 week (for OCUM-2MLN cells) or 3 weeks (for OCUM-12 
cells) when the major axis of the tumors was approximately 10 mm 
long. For the orthotopic transplantation model, a total of 5 × 10  6   
cells in 50   µ  L of DMEM were injected into the gastric wall of each 
mouse (n = 8 mice per group) and allowed to grow for 1 week when 
tumor was approximately 5 mm in diameter.   
    Tumor Volume Measurement 
  The volume of subcutaneous xenograft tumors was measured 
externally every other day until the end of the evaluation period. 
Tumor volume was estimated by using the equation,   v   = (  ab    2  )/2, 
where   v   is volume,   a   is the length of the major axis of the tumor, 
and   b   is the length of its minor axis. The relative tumor volume was 
then calculated by dividing tumor volume on a given experimental 
day by that on day 0 (the day of initiation of treatment or evalua-
tion). For orthotopic xenograft tumors, the tumor area on the 
gastric wall was measured by opening the abdomen on experi-
mental day 14 and at the end of the evaluation period (day 21). 
The major and minor axes of tumors were measured with Adobe 
Photoshop software (Adobe Systems, Mountain View, CA), and 
tumor areas on the gastric wall were calculated with ImageJ 
software (National Institutes of Health, Bethesda, MD). Relative 
tumor area was obtained by dividing the area on day 21 by that 
on day 14.   
    RNA Isolation and Quantitative Real-Time Reverse 
Transcription-PCR 
  Total RNAs from gastric carcinoma cells or excised subcutaneous 
tumors were extracted with the RNeasy Mini Kit (QIAGEN, 
Valencia, CA). Sources of RNAs were as follows: cultured 2MLN, 
2MLN-GFP, and 2MLN-dnT    RII cells at 0, 1, and 24 hours treated 
with TGF-     ligand at 1 ng/mL or left untreated (  see     Figure 1, B  ); 
cultured 2MLN-GFP and 2MLN-dnT    RII cells at 24 hours 
treated with TGF-     ligand at 1 ng/mL or left untreated, and sub-
cutaneous tumors generated from these cells that were allowed to 
grow for 3 weeks in vivo (  see     Figure 2  ); cultured 2MLN-GFP, 
2MLN-GFP+miTSP-1, and 2MLN-dnT    RII cells treated with 
TGF-     ligand at 1 ng/mL or left untreated, and subcutaneous 
tumors generated from these cells in vivo that were allowed to 
grow for 3 weeks (  see     Figure 4  ); and cultured OCUM-12-GFP and 
OCUM-12-dnT    RII cells at 24 hours treated with TGF-     ligand 
at 1 ng/mL or left untreated (  see     Figure 5  ). First-strand cDNAs 
were synthesized with the Quantitect Reverse Transcription kit 
(QIAGEN) with random hexamer primers. Quantitative real-time 
reverse transcription (RT)-PCR analysis was performed with the 
7500 Fast Real-Time PCR system (Applied Biosystems, Foster 
City, CA) with the primers, as shown in   Supplementary Table 1   
(available online). Each experiment was conducted two times, each 
sample was assayed in triplicate, and data were averaged. Data 
from one representative experiment are shown.                   jnci.oxfordjournals.org    JNCI | Articles 595
    Microarray Analysis of Gene Expression in 2MLN-GFP or 
2MLN-dnT    RII Tumors 
  Tissue samples from subcutaneous 2MLN-GFP or 2MLN-dnT  -
  RII tumors were digested with collagenase (Worthington, 
Lakewood, NJ; 1 mg/mL) at 37°C for 1 hour, followed by treat-
ment with 0.25% trypsin  –  EDTA (Invitrogen) at 37°C for 15 
minutes. The resulting single-cell suspension was subjected to 
magnetic cell sorting (MACS  ®  ) with magnetic microbeads conju-
gated to CD326 antibody (Miltenyi Biotec, Auburn, CA      ) to sepa-
rate CD326-positive human cancer cells from CD326-negative 
mouse stromal cells. Total RNAs from the isolated cancer cells 
were purified with the RNeasy Mini Kit (QIAGEN) and used for 
microarray analysis. Biotin-labeled complementary RNAs were 
synthesized and hybridized to the oligonucleotide microarray, 
GeneChip Human Genome U133 Plus2.0 (Affymetrix, Santa 
Clara, CA), according to Affymetrix technical manual. Gene 
expression data were normalized by use of the MAS5 algorithm 
according to the manufacturer’s instruction. DAVID functional 
annotation clustering (  26  ) with the Kyoto Encyclopedia of Genes 
and Genomes pathway database (  http://genome.ad.jp/kegg/  ) was 
used for pathway analysis of the top 50 most variable probe sets of 
the GeneChip.   
    Histochemistry and Immunohistochemistry in Mouse 
Tissues 
  Excised mouse tissue samples were fixed for 1 hour in 10% 
neutral-buffered formalin at room temperature, washed overnight 
in phosphate-buffered saline containing 10% sucrose at 4°C, and 
embedded in optimal cutting temperature compound (Tissue-Tek; 
Sakura Finetek, Tokyo, Japan). Some samples were then snap fro-
zen in a dry ice  –  acetone bath for immunohistochemistry, and 
other samples were fixed overnight in 4% paraformaldehyde and 
then embedded in paraffin for hematoxylin  –  eosin staining or 
AZAN staining to visualize collagen fibers. Frozen samples were 
  Figure 1    .       Disruption of TGF-     in gastric cancer cells 
and tumors. We used parental OCUM-2MLN cells, 
2MLN cells expressing GFP (termed 2MLN-GFP 
cells) as a control, and 2MLN cells expressing a 
dnT    RII (termed 2MLN-dnT    RII cells).   A  ) TGF-     sig-
nal transduction in the cells. Immunoblot analysis 
was used to compare the level of phosphorylated 
Smad2 (phospho-Smad2) with that of Smad2 and 3 
as control, in parental OCUM-2MLN cells (  lanes   –     = 
cells carry no constructs), 2MLN-GFP cells (  lanes 
GFP  ), and 2MLN-dnT    RII cells (  lanes dnT    RII  ), 
treated with TGF-    3 (1 ng/mL) or left untreated for 1 
hour. Expression of dnT    RII protein (by use of 
hemagglutinin [HA] tag), and that of GFP, as a con-
trol for lentiviral infection was also determined by 
immunoblot analysis. The cells were subjected to 
immunoblot analysis with antibodies against the 
proteins indicated to the   left  . The experiment was 
conducted two times, and data from one representa-
tive experiment are shown.   B  ) Human Smad7 mRNA 
expression. Quantitative real-time polymerase chain 
reaction was used to assess the level of expression 
of human Smad7 mRNA in all three cell lines after 
treatment with TGF-    3 (1 ng/mL), as indicated. The 
experiment was conducted two times, each sample 
was assessed in triplicate, and data were averaged. 
Data from one representative experiment are shown. 
  C  ) Proliferation of gastric cancer cells in the pres-
ence of TGF-    3. Cells were treated with TGF-    3 
(1 ng/mL) in 10% fetal bovine serum for 3 days; control 
cells were not treated with TGF-    3. The experiment 
was conducted two times, each sample was assessed 
in triplicate, and data were averaged. Data from one 
representative experiment are shown.   D  ) Growth of 
2MLN-GFP and 2MLN-dnT    RII tumors in nude mice 
for 10 days. Cells were subcutaneously transplanted 
into nude mice (n = 8 mice per group).   E  ) Growth of 
orthotopic 2MLN-GFP and 2MLN-dnT    RII tumors in 
nude mice. Cells were transplanted into the gastric 
wall of nude mice (n = 8 mice per group).   Left)   
Macroscopic appearance of representative samples 
of excised gastric wall with an orthotopic tumor. 
  Right)   Relative areas of the 2MLN-GFP and 2MLN-
dnT    RII tumors. Scale bar = 10 mm.   Error bars   = 
95% conﬁ  dence intervals. All   P   values (two-sided) 
were calculated by using a Student’s   t   test, except 
for that in (  D  ), which was calculated by using a two-
way repeated measures analysis of variance. dnT  -
  RII = dominant-negative TGF-     type II receptor; 
GFP = green ﬂ  uorescent protein; TGF-     = transform-
ing growth factor     .       
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further sectioned at a thickness of 10   µ  m with a cryostat, briefly 
fixed with 10% formalin, and then incubated with primary and 
secondary antibodies. Formalin-fixed samples of subcutaneous 
tumors and orthotopic tumors were subjected to hematoxylin  –  eosin 
and AZAN staining (  see     Figures 2, A   and   4, C   and   Supplementary 
Figure 1, A  , available online). Frozen samples of subcutaneous 
tumors were immunostained with anti-PECAM-1 and anti-rat 
Alexa 594 antibodies (  see     Figures 2, D   and   4, B  ), or with anti-
hemagglutinin and anti-rat Alexa 594 antibodies with TOTO-3 
nuclear stain (  see     Figure 3, B  ). Frozen samples of orthotopic 
tumors were immunostained with anti-PECAM-1 and anti-rat 
Alexa 594 antibody (  Supplementary Figure 1, B  , available online).                   
    Enzyme-Linked Immunosorbent Assay 
  Production of TGF-    1 by 2MLN-GFP and 2MLN-dnT    RII 
cells was determined with a sandwich enzyme immunoassay tech-
nique by using a Quantikine human TGF-    1 immunoassay (R&D 
Systems), according to the manufacturer’s instruction. A total of 
1 × 10  6   cells were cultured in 1% fetal bovine serum in six-well plates 
for 24 hours, and 100   µ  L of conditioned medium was removed and 
treated with 20   µ  L of 1 M HCl for 10 minutes, followed by neu-
tralization with 20   µ  L of 1.2 M NaOH in 0.5 M HEPES (pH 7.4). 
Without this acidification step with 1 M HCl, levels of TGF-    1 in 
the conditioned medium could not be detected by the enzyme-linked 
immunosorbent assay. The samples were then pipetted into the 
wells of the microplate that had been precoated with a monoclonal 
antibody specific for TGF-    1 and incubated for 2 hours at room 
temperature. Subsequently, an enzyme-linked polyclonal antibody 
specific for TGF-    1 was added to the wells and incubated for 
additional 2 hours at room temperature to sandwich the TGF-    1 
ligand. After a wash to remove unbound antibody  –  enzyme reagent, 
a substrate solution consisting of hydrogen peroxide and tetrame-
thylbenzidine was added to the wells, and the intensity of the color 
developed was determined with a microplate reader (BIO-RAD, 
Hercules, CA). Each experiment was conducted two times, each 
sample point was assessed in triplicate, and data were averaged. 
Data from one representative experiment are shown.   
    Reduction of Thrombospondin-1 Expression by Use of 
MicroRNAs 
  The Block-iT Pol II miR RNAi expression system (Invitrogen) 
was used to knockdown the expression of thrombospondin-1. A 
microRNA construct against thrombospondin-1 was cloned into 
the pcDNA6.2-GW/EmGFP-mir vector (Invitrogen) after anneal-
ing the oligonucleotide 5 ′  -AGAACTCAGTTACCATCTGCA-3  ′  , 
which was designed to knockdown the expression of thrombos-
pondin-1 by using BLOCK-iT RNAi Designer (Invitrogen). The 
EmGFP-miR thrombospondin-1 expression site was then inserted 
  Figure 2    .       Histological characterization of 2MLN-
GFP and 2MLN-dnT    RII xenograft tumors from 
nude mice.   A  ) Fibrotic tissue in subcutaneous 
2MLN-GFP (GFP) or 2MLN-dnT    RII (dnT    RII) 
xenograft tumors.   Left)   On day 14, ﬁ  brotic areas 
of tumor sections were visualized by AZAN 
staining and examined via light microscopy. 
Scale bars = 100   µ  m.   Right)   Quantiﬁ  cation 
of ﬁ   brotic areas (n = 9 with each condition). 
  B  ) Expression of human and mouse procollagen 
I mRNAs.   Left)   2MLN-GFP subcutaneous tumors 
in nude mice.   Middle)   2MLN-dnT    RII subcutane-
ous tumors in nude mice.   Right)   TGF-     treat-
ment in 2MLN-GFP and 2MLN-dnT    RII cell lines. 
Cells were treated with TGF-     for 24 hours or left 
untreated (as indicated) and assayed for procol-
lagen I mRNA with quantitative real-time poly-
merase chain reaction. Each experiment was 
conducted two times, each sample was assessed 
in triplicate, and data were averaged. Data from 
one representative experiment of these are 
shown.   C  ) Concentrations of human TGF-    1 
protein in 2MLN-GFP and 2MLN-dnT    RII cell 
culture supernatants. The level of TGF-    1 pro-
tein was determined by an enzyme-linked immu-
nosorbent assay with an antibody speciﬁ  c for 
TGF-    1. The experiment was conducted two 
times, each sample was assessed in triplicate, 
and data were averaged. Data from one repre-
sentative experiment of these are shown. 
  D  ) Vascular density in 2MLN-GFP and 2MLN-
dnT    RII xenograft tumors. Vascular density was 
determined by immunostaining with an anti-
body against PECAM-1 (n = 6 mice per group).   Left)   Micrographs of 
immunostained 2MLN-GFP and 2MLN-dnT    RII xenograft tumor sec-
tions. PECAM-1  –  positive areas are shown in   red   (n = 6 with each condi-
tion). Scale bars = 100   µ  m.   Right)   Percent PECAM-1  –  positive areas in 
2MLN-GFP and 2MLN-dnT    RII xenograft tumor sections per micro-
scopic ﬁ  eld (n = 6 with each condition).   E  ) Expression of hTSP-1 mRNA. 
  Left)   2MLN-GFP and 2MLN-dnT    RII tumors in nude mice.   Right)   2MLN-
GFP and 2MLN-dnT    RII cells treated with TGF-     or left untreated for 24 
hours in vitro, as indicated. Each experiment was conducted two times, 
each sample was assessed in triplicate, and data were averaged. Data 
from one representative experiment are shown.   Error bars   = 95% con-
ﬁ   dence intervals. All   P   values (two-sided) were calculated with a 
Student’s   t   test. dnT    RII = dominant-negative TGF-     type II receptor; 
GFP = green ﬂ  uorescent protein; TGF-     = transforming growth factor     ; 
hTSP-1 = human thrombospondin-1; PECAM-1 = platelet  –  endothelial 
cell adhesion molecule-1.       
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into the pDONR221 vector (Invitrogen) by the BP recombination 
reaction according to the manufacturer’s instructions, followed by 
its insertion into multicloning site of the lentiviral vector pCSII-
EF-MCS LR recombination reaction (Invitrogen), according to 
the manufacturer’s instruction. Stably transfected 2MLN-GFP 
cells, termed 2MLN-GFP+miTSP-1, in which the expression 
of thrombospondin-1 was silenced, were established by use of 
the lentiviral infection system by the methods as described 
above (  23  ).   
    Treatment With Angiogenesis Inhibitors In Vivo 
  A small-molecule inhibitor of angiogenesis, sorafenib (Nexavar; 
Bayer Health Care, Leverkusen, Germany), was dissolved at 10 
mg/mL in dimethyl sulfoxide as stock solution (ie, 5 mL of dime-
thyl sulfoxide was added to one-fourth of a 200-mg sorafenib 
tablet). An 80-  µ  L aliquot of the sorafenib stock solution (800   µ  g of 
sorafenib) was diluted with 170   µ  L of phosphate-buffered saline to 
a final concentration of 3.2 mg/mL. One week after subcutaneous 
transplantation with 2MLN-GFP or 2MLN-dnT    RII cells or 4 
weeks after subcutaneous transplantation with OCUM-12-GFP 
and OCUM-12-dnT    RII cells (n = 6 mice per group), sorafenib or 
a vehicle control was administered intraperitoneally to BALB/c 
nude mice every day. Fifty micrograms of anti-vascular endothelial 
growth factor (VEGF) neutralizing monoclonal antibody (MAB293; 
R&D Systems) (2.5 mg/kg) dissolved in 250   µ  L of phosphate-
buffered saline to a concentration of 0.2 mg/mL or vehicle was 
intraperitoneally injected into these nude mice (n = 6 mice per 
group) twice a week for 14 days.   
    Immunohistochemistry of Human Gastric Cancer Tissues 
  We examined 102 consecutive surgical samples from patients with 
gastric cancer at the Osaka City University Hospital, Osaka, Japan, 
  Figure 3    .        Characterization of xenograft 
tumors with a mixture of equal numbers of 
2MLN-GFP (GFP) and 2MLN-dnT    RII (dnT  -
  RII) cells.  A  ) Developmental model of tumors 
inoculated with a mixture of 2MLN-GFP and 
2MLN-dnT    RII. Equal amounts of the 2MLN-
GFP and 2MLN-dnT    RII cells were mixed and 
transplanted into nude mice. The composi-
tion of tumors generated with a mixture of 
2MLN-GFP and 2MLN-dnT    RII cells was com-
pared with that of tumors generated with 
2MLN-GFP or 2MLN-dnT    RII cells alone to 
investigate whether the tumor microenviron-
ment serves as a major determinant of tumor 
growth.   B  ) Distribution of 2MLN-GFP cells 
(GFP,   green  ) and 2MLN-dnT    RII cells (as 
shown by a hemagglutinin tag that was 
detected with anti-hemagglutinin antibody, 
  red  ) in mixed-cell tumors. 2MLN-GFP cells were 
identiﬁ   ed by GFP ﬂ  uorescence,  and  2MLN-
dnT    RII cells were identiﬁ  ed by immuno-
histochemistry staining with an antibody 
speciﬁ  c for hemagglutinin and with nuclear 
counterstaining with TOTO-3.   Left)   Micro-
graphs of sections from tumors generated 
with 2MLN-GFP cells alone, 2MLN-dnT    RII 
cells alone, or a mixture of both cell lines. 
Scale bars = 100   µ  m.   Right)   Percent hemag-
glutinin-positive areas and GFP-positive 
areas (n = 9 with each condition).   C  ) Vascular 
areas in tumors generated with 2MLN-GFP 
cells alone, 2MLN-dnT    RII cells alone, or a 
mixture of both cell types. Vascular areas 
were identiﬁ  ed by immunostaining with anti-
body against PECAM-1 (n = 3 in each condi-
tion).   Error bars   = 95% conﬁ  dence intervals. 
All   P   values (two-sided) were calculated 
using the Student’s   t   test. dnT    RII = dominant-
negative TGF-     type II receptor; GFP = green 
ﬂ   uorescent protein; TGF-     = transforming 
growth factor     ; PECAM-1 = platelet  –  endothelial 
cell adhesion molecule-1.       
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which were obtained under a blanket written informed consent. 
Tissue sections were prepared from paraffin blocks and then incu-
bated in antigen retrieval solution (Histo VT one; Nacalai Tesque, 
Kyoto, Japan) at 105°C for 20 minutes for thrombospondin-1 and 
for 40 minutes for phosphorylated Smad2. Sections were immunos-
tained with primary and secondary antibodies. The primary antibod-
ies used were       rabbit anti-phosphorylated Smad2 monoclonal 
antibody and mouse anti-thrombospondin-1 monoclonal antibody. 
Secondary antibodies used were Alexa 488  –  conjugated goat anti-
rabbit IgG antibody and/or Alexa 594  –  conjugated goat anti-mouse 
IgG antibody and were visualized by use of a Zeiss LSM510 Meta 
confocal microscope (Thornwood, NY) for immunohistochemistry 
and GFP fluorescence, and with an Olympus (Tokyo, Japan) 
AX80 microscope for hematoxylin  –  eosin and AZAN staining. 
Sections were scored positive when more than approximately 10% 
of the cancer cells were moderately or strongly stained, according to 
a recent study (  27  ). In control experiments, the primary antibodies 
were omitted.   
    Statistical Analyses 
  Results were analyzed statistically by two-sided Student’s   t   tests or 
by two-way repeated measures analysis of variance (ANOVA) tests 
with JMP6 software (SAS Institute, Raleigh, NC), where applica-
ble. Results of immunohistochemistry for human surgical samples 
were analyzed with the       2   test. Results were considered to be sta-
tistically significant at   P   < .05. All statistical tests were two-sided.     
    Results 
    Disruption of TGF-     Signaling and Growth of Xenografted 
Tumors in Mice 
  We investigated the role of TGF-     signaling in human diffuse-
type gastric carcinoma by transfecting OCUM-2MLN cells with 
lentiviral constructs expressing dnT    RIIs or a GFP control. 
We first determined whether the parental OCUM-2MLN cells 
and transfected 2MLN-GFP and 2MLN-dnT    RII cells respond 
to TGF-     in vitro by expressing GFP or dnT    RII, by use of 
  Figure 4    .        Expression of TSP-1 
and tumor growth in nude 
mice.   A  ) Tumor volume and 
TSP-1 expression. The 2MLN-
dnT    RII cells, which stably 
express TSP-1, are termed 
2MLN-dnT    RII+TSP-1. Volumes 
of the subcutaneous tumors 
produced by 2MLN-GFP, 
2MLN-dnT    RII, and 2MLN-
dnT    RII+TSP-1 cells were 
determined 7 days after inocu-
lation (n = 6 mice per group). 
  B  ) Vascular density at 7 days 
after inoculation as determined 
by immunostaining for 
PECAM-1.   Left)   Immuno-
staining with antibody against 
PECAM-1. Scale bars = 100   µ  m. 
  Right)   Percent PECAM-1  –
  positive area (n = 3 with each 
condition).   C  ) Fibrotic tissue as 
determined by AZAN staining 
in the subcutaneous tumors 
7 days after inoculation.   Left)   
Micrographs with ﬁ  brotic  tis-
sue stained   blue   by AZAN 
staining. Scale bars = 100   µ  m. 
  Right)   Percent AZAN-positive 
area (n = 3 with each condi-
tion).   D  ) The effect of miTSP-1 
mRNA expression in the gas-
tric cancer cells as determined 
by TSP-1 mRNA expression. The 
2MLN-GFP, 2MLN-GFP+miTSP-1, 
and 2MLN-dnT    RII cells were 
treated with TGF-     or left 
untreated for 24 hours in vitro, 
and expression of TSP-1 mRNA 
was compared among the cell 
lines. The experiment was conducted two times, each sample was 
assayed in triplicate, and data were averaged. Data from one representa-
tive experiment are shown.   E  ) Growth curves of 2MLN-GFP, 2MLN-
GFP+miTSP-1, and 2MLN-dnT    RII xenograft tumors in nude mice (n = 6 
in each condition). In 2MLN-GFP+miTSP-1 cells, the expression of TSP-1 
was reduced by use of the miTSP-1. Tumor volume is shown relative to 
the average volume in each condition at day 0 after starting evaluation.   F  ) 
Expression of TSP-1 mRNA in the 2MLN-GFP, 2MLN-GFP+miTSP-1, and 
2MLN-dnT    RII tumors in vivo. Experiment was conducted two times, 
each sample was assessed in triplicate, and data were averaged. Data 
from one representative experiment are shown.   Error bars   = 95% conﬁ  -
dence intervals. All   P   values (two-sided), except for those in (  E  ), were 
calculated using the Student’s   t   test.   P   values in (  E  ) were calculated by 
two-way repeated measures analysis of variance. dnT    RII = dominant-
negative TGF-     type II receptor; miTSP-1 = microRNA against thrombos-
pondin-1; GFP = green ﬂ  uorescent protein; TGF-     = transforming growth 
factor     ; TSP-1 = thrombospondin-1; PECAM-1 = platelet  –  endothelial cell 
adhesion molecule-1.       
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immunoblotting. We found that GFP was expressed in the 
2MLN-GFP control cells and dnT    RII was expressed in 2MLN-
dnT    RII cells (  Figure 1, A  ). In contrast to the parental 2MLN 
cells and GFP-transfected 2MLN-GFP cells, TGF-      –  induced 
phosphorylated Smad2 was not detected in 2MLN-dnT    RII cells 
(  Figure 1, A  ). We next used quantitative real-time RT-PCR analy-
sis to show that the induction of Smad7 mRNA, a well-known 
target of TGF-     signaling, by TGF-     was lower in the 2MLN-
dnT    RII cells than in OCUM-2MLN or 2MLN-GFP cells 
(  Figure 1, B  ). 2MLN, 2MLN-GFP, and 2MLN-dnT    RII cells 
had similar proliferation rates, and the proliferation rates of these 
cells were not statistically significantly inhibited after TGF-     
treatment (  Figure 1, C  ). 
  Next, 2MLN-GFP or 2MLN-dnT    RII cells were subcutane-
ously transplanted into nude mice (n = 8 mice in each group), and 
tumor size was measured every other day until day 10. Although 
the proliferation of these cell types did not differ in vitro, the vol-
umes of 2MLN-dnT    RII tumors were statistically signiﬁ  cantly 
larger than those of 2MLN-GFP tumors (  Figure 1, D  ; mean volume 
on day 10 relative to that on day 0 of 2MLN-dnT    RII tumors = 
3.49 and of 2MLN-GFP tumors = 2.46, difference = 1.02, 95% 
conﬁ  dence interval [CI] = 0.21 to 1.84; for group effect,   P   = .003; 
     
  Figure 5    .         Administration of sorafenib and 
tumor growth in nude mice.   A  ) Growth curve of 
xenografted 2MLN-GFP and 2MLN-dnT    RII 
tumors and sorafenib treatment. Mice bearing 
tumors were treated with 800   µ  g of sorafenib 
or with vehicle, as indicated, every day for 14 
days (n = 6 mice per group). The representative 
macroscopic appearance of the tumors at day 
7 is shown in the   bottom panels  .   B  ) Growth 
curve of xenografted 2MLN-GFP and 2MLN-
dnT    RII tumors in the presence and absence of 
anti-VEGF neutralizing antibody (n = 6 mice per 
group). Mice bearing tumors were treated for 
14 days with 50   µ  g of anti-VEGF antibody or 
vehicle, as indicated, twice a week. The repre-
sentative macroscopic appearance of the 
tumors at day 7 is shown in the   bottom panels  . 
  C  ) Expression of human TSP-1 mRNA and 
treatment with TGF-    . TSP-1 mRNA expression 
was determined by quantitative real-time 
reverse transcription  –  polymerase chain reac-
tion in the control OCUM-12-GFP (GFP) and 
OCUM-12-dnT    RII (dnT    RII) cells that were 
treated with TGF-     (1 ng/mL) or left untreated 
for 24 hours in vitro. The experiment was con-
ducted two times, each sample was assessed 
in triplicate, and data were averaged. Data 
from one representative experiment of these 
are shown.   D  ) Growth curves of xenografted 
OCUM-12-GFP and OCUM-12-dnT    RII tumors 
and sorafenib treatment. Mice bearing tumors 
were treated with 800   µ  g of sorafenib or with 
vehicle, as indicated, every day for 14 days (n = 
7 mice per group). The representative macro-
scopic appearance of the tumors at day 14 is 
shown in the   bottom panels  .   Error bars   = 95% 
conﬁ  dence intervals.   P   values for (  A  ), (  B  ), and 
(  D  ) were calculated by two-way repeated mea-
sures analysis of variance. Those for (  C  ) were 
calculated with a Student’s   t   test, two-sided. 
DMSO = dimethyl sulfoxide (vehicle). dnT    RII = 
dominant-negative TGF-     type II receptor; GFP = 
green ﬂ   uorescent protein; VEGF = vascular 
endothelial growth factor; TGF-     = transforming 
growth factor     ; TSP-1 = thrombospondin-1.       600   Articles | JNCI  Vol. 101, Issue 8  |  April 15, 2009
and for the sampling time effect and the dnT    RII group effect × 
sampling time effect,   P   < .001, by a two-way repeated measures 
ANOVA test for tumor growth). We also orthotopically trans-
planted 2MLN-GFP or 2MLN-dnT    RII cells into the gastric 
wall of nude mice and determined tumor size on days 14 and 21 
after implantation. The relative tumor area of 2MLN-dnT    RII 
(2.98) was statistically signiﬁ  cantly larger than that of 2MLN-GFP 
(1.59) (  Figure 1, E  ) (difference = 1.39, 95% CI = 0.87 to 1.91;   P   < 
.001, n = 8 mice in each group). 
  To explore factors responsible for the increased growth of the 
2MLN-dnT    RII tumors in vivo, we used microarray analysis to 
identify differentially expressed human genes in the subcutane-
ously transplanted 2MLN-GFP and 2MLN-T    RII tumors and 
then used pathway analysis with the DAVID program to annotate 
the list of differentially expressed genes in these tumors. The 
DAVID program provides batch annotation and gene ontology 
term enrichment analysis to highlight the most relevant gene 
ontology terms associated with a given gene list (  26  ). The analysis 
of our microarray data by the DAVID program identiﬁ  ed three 
pathways as differentially activated pathways: cell communication, 
interactions between the extracellular matrix and the receptors, 
and focal adhesion (  Supplementary Table 2  , available online). All 
three pathways included   COL1A1  ,   THBS1  , and   LAMC2  , whose 
expression levels were substantially lower in 2MLN-dnT    RII 
tumors than in 2MLN-GFP tumors (  Supplementary Table 2  , 
available online).   COL1A1   encodes procollagen I, which is involved 
in ﬁ  brosis, and   THBS1   encodes thrombospondin-1, which is an 
angiogenesis inhibitor.   LAMC2   encodes laminin-    2 and was also 
included in all the three pathways. Although the increased expres-
sion of laminin-    2 has been reported to be involved in invasion of 
certain cancers (  28  ), the importance of its decreased expression in 
cancer remains unknown. Therefore, we further analyzed the rela-
tionship between the increased growth of the 2MLN-dnT    RII 
tumors and tumor microenvironment, especially ﬁ  brosis, with 
a focus on procollagen I, and angiogenesis, with a focus on 
thrombospondin-1.   
    Reduction of Stromal Fibrosis by dnT    RII 
  We analyzed the tumor microenvironment by determining the 
degree of fibrosis in the subcutaneous and orthotopic tumor tis-
sues, as shown by AZAN staining of collagen fibers (  Figure 2, A   
and   Supplementary Figure 1, A  , available online). In both tumor 
types, the area of fibrosis as determined by AZAN staining was 
statistically significantly lower in the 2MLN-dnT    RII tumors 
than in the 2MLN-GFP tumors (for subcutaneous tumors, 
2MLN-dnT    RII had 6.1% and 2MLN-GFP had 30.1% [n = 9 
mice per group], difference = 24.0%, 95% CI = 14.4% to 33.6%, 
  P   < .001; and for orthotopic tumors, 2MLN-dnT    RII tumors had 
19.8% and 2MLN-GFP tumors had 47.0%, n = 9, difference = 
27.2%, 95% CI = 20.0% to 34.4%,   P   < .001). 
  Microarray analysis revealed that the COL1A1 expression was 
lower in the 2MLN-dnT    RII tumors than in the 2MLN-GFP 
tumors. These results were validated with quantitative real-time 
RT-PCR with human COL1A1  –  speciﬁ  c primers and subcutane-
ous tumor samples (expression in 2MLN-dnT    RII tumors was 
1.01 arbitrary units and that in 2MLN-GFP tumors was 17.46 
arbitrary units, n = 3, difference = 16.4, 95% CI = 12.3 to 20.6 
arbitrary units,   P   < .001) (  Figure 2, B  , left panel). In the same 
tumors, expression of the mouse Col1A1 mRNA was similar in 
2MLN-dnT    RII and 2MLN-GFP tumors (  Figure 2, B  , middle 
panel;   P   = .026). In cultured cells, expression of the human 
COL1A1 mRNA was induced by TGF-     in the 2MLN-GFP cells 
but not in the 2MLN-dnT    RII cells (  Figure 2, B  , right panel). 
Secretion of TGF-    1 as determined by an enzyme-linked immu-
nosorbent assay revealed that production of TGF-    1 was lower in 
2MLN-dnT    RII cells (22.1 pg/mL) than in 2MLN-GFP cells 
(552.4 pg/mL) (difference = 530.3 pg/mL, 95% CI = 502.7 to 
558.0 pg/mL,   P   < .001) (  Figure 2, C  ). Thus, the material in the 
extracellular matrix in these tumors appears to be derived primarily 
from the gastric carcinoma cells and that the increased production 
of these extracellular matrix materials may be induced by TGF-    1 
that is produced by the gastric carcinoma cells.   
    Induction of Tumor Angiogenesis by dnT    RII 
  We next examined tumor angiogenesis, another important compo-
nent of the tumor microenvironment, in 2MLN-dnT    RII and 
2MLN-GFP tumors in vivo. We used immunohistochemistry to 
determine vascular density in tumors with a specific marker of 
vascular endothelium, PECAM-1 (  Figure 2, D   and   Supplementary 
Figure 1, B  , available online). In subcutaneous tumors, the 
PECAM-1  –  positive area was statistically significantly higher in 
2MLN-dnT    RII tumors (8.91% per microscopic field) than in 
2MLN-GFP tumors (4.78%) (n = 6, difference = 4.13%, 95% CI = 
1.31% to 6.94%;   P   = .008) (  Figure 2, D  ). In orthotopic tumors, the 
PECAM-1  –  positive area was also statistically significantly higher 
in 2MLN-dnT    RII tumors (1.95% per microscopic field) than 
in 2MLN-GFP tumors (0.27%) (n = 7, difference = 1.67%, 95% 
CI = 0.46% to 2.88%;   P   = .013) (  Supplementary Figure 1, B  , available 
online). 
  The   THBS1   gene was included in all pathways selected by 
DAVID analysis, and the microarray analysis showed that the 
expression of THBS1 was lower in the 2MLN-dnT    RII tumors 
than in the 2MLN-GFP tumors (  Supplementary Table 2  , available 
online). We used quantitative RT-PCR with human THBS1  –
  speciﬁ  c primers to conﬁ  rm that the expression of THBS1 mRNA 
from human carcinoma cells was lower in the 2MLN-dnT    RII 
tumors (0.13 arbitrary unit) than in the 2MLN-GFP tumors (2.20 
arbitrary units) (difference = 2.07 arbitrary units, 95% CI = 1.92 to 
2.22 arbitrary units;   P   < .001) (  Figure 2, E  , left panel). Moreover, 
expression of thrombospondin-1 was potently induced by TGF-     
in the 2MLN-GFP cells in vitro but not in the 2MLN-dnT    RII 
cells (  Figure 2, E  , right panel). In addition to thrombospondin-1, 
VEGF has been reported to be involved in angiogenesis in the 
Smad4-deﬁ  cient pancreatic tumor model (  29  ). However, the level 
of VEGF expression, as determined with primers speciﬁ  c for both 
human and mouse VEGF, was similar between 2MLN-GFP and 
2MLN-dnT    RII cells in vivo and in vitro (data not shown), indicat-
ing that decreased expression of thrombospondin-1 may be involved 
in the enhanced angiogenesis in the 2MLN-dnT    RII tumors.   
    Phenotype of Tumors Containing a Mixture of Both 
2MLN-GFP and 2MLN-dnT    RII Cells 
  The results described above strongly suggest that regulation of 
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signaling may be important to tumor formation in diffuse-type 
gastric carcinomas; however, it is still possible that the changes in 
tumor growth rate may be induced by other autonomous factor(s) 
in the cancer cells. To investigate further whether the tumor 
microenvironment serves as a major determinant of tumor growth 
in this model, we mixed equal amounts of the 2MLN-GFP and 
2MLN-dnT    RII cells and transplanted the cell mixture into nude 
mice (  Figure 3, A  ). If the tumor microenvironment plays a major 
role in tumor growth, then the 2MLN-GFP+dnT    RII tumors 
should contain equal number of both cell types (  Figure 3, A  ). In 
contrast, if the 2MLN-dnT    RII portion of the tumor grows faster 
in cell-autonomous fashion, then the 2MLN-GFP+dnT    RII 
tumors should be composed mainly of 2MLN-dnT    RII cells. 
Histological examination of 2MLN-GFP+dnT    RII tumors with 
GFP fluorescence and by use of hemagglutinin antibody to detect 
the 2MLN-GFP and 2MLN-dnT    RII cells, respectively, revealed 
that the 2MLN-GFP+dnT    RII tumors contain almost equal 
number of the two cell types (  P   = .56) (  Figure 3, B  ). We also exam-
ined angiogenesis in 2MLN-GFP+dnT    RII tumors by use of 
PECAM-1 immunostaining and found that the level of vascular 
density in the mixed-cell tumor (2.61% per microscopic field) was 
intermediate between that of 2MLN-dnT    RII tumors (4.22%) 
and 2MLN-GFP tumors (1.34%) (difference with 2MLN-dnT  -
  RII tumors = 1.61, 95% CI = 0.37% to 2.86%,   P   = .023 [n = 3]; 
difference with 2MLN-GFP tumors = 1.27%, 95% CI = 0.73% to 
1.81%,   P   = .003 [n = 3]) (  Figure 3, C  ).   
    Inhibition of Angiogenesis and Growth of 2MLN-dnT    RII 
Tumors 
  To determine whether decreased thrombospondin-1 expression is 
involved in the accelerated proliferation of 2MLN-dnT    RII 
tumors, we used a lentivirus system to introduce the gene for 
thrombospondin-1 into the 2MLN-dnT    RII cells, and these cells 
were injected into mice to form tumors. At day 7, the volume of 
2MLN-dnT    RII tumors that expressed exogenous thrombospon-
din-1 (3.08 × 10  3   mm 
3  ) was lower than that of 2MLN-dnT    RII 
tumors alone (12.0 × 10  3   mm 
3  ) (difference = 8.94 × 10 
3   mm 
3  , 95% 
CI = 5.82 × 10  3   to 12.1 × 10 
3   mm 
3  ,   P   < .001 [n = 6]) and was similar 
to that of control 2MLN-GFP tumors that expressed GFP (2.81 × 10  3   
mm  3  ; difference = 0.27 × 10 
3   mm 
3  , 95% CI =     1.67 × 10 
3   to 
2.21 × 10  3   mm 
3  ,   P   = .76 [n = 6]) (  Figure 4, A  ). Immunostaining of 
the tumors with an antibody against PECAM-1 protein demon-
strated that the vascular density of the 2MLN-dnT    RII tumors 
was reduced by the introduction of thrombospondin-1 (1.90% per 
microscopic field) compared with that of 2MLN-dnT    RII tumors 
alone (7.74%; difference = 5.84%, 95% CI = 4.21% to 7.48%,   P   < 
.001 [n = 3]) or that of 2MLN-GFP tumors as control (1.85% per 
microscopic field; difference = 0.05%, 95% CI =     1.64% to 
1.73%,   P   = .9 [n = 3]) (  Figure 4, B  ). In contrast, AZAN staining 
showed that the degree of fibrosis was not statistically significantly 
changed by introduction of thrombospondin-1 (  Figure 4, C  ). 
  We obtained additional support for the ﬁ  nding that decrease 
in thrombospondin-1 is involved in the accelerated growth of the 
2MLN-dnT    RII tumors by knocking down the expression of 
thrombospondin-1 in the 2MLN-GFP cells with an RNA inter-
ference approach. The 2MLN-GFP cells expressing the 
microRNA  construct against thrombospondin-1 were termed 
2MLN-GFP+miTSP-1 cells. Expression of thrombospondin-1 
was lower in the 2MLN-GFP+miTSP-1 cells than in 2MLN-GFP 
cells in vitro (  Figure 4, D  ). When these cells were inoculated to 
mice to form tumors, knockdown of thrombospondin-1 resulted in 
the volumes of 2MLN-GFP+miTSP-1 tumors being larger than 
those of 2MLN-GFP tumors (  Figure 4, E  ; mean volume of 
2MLN-GFP+miTSP-1 tumor on day 14 relative to that on day 0 
after starting evaluation = 4.91 and that of 2MLN-GFP tumor = 3.79; 
difference = 1.12, 95% CI = 0.80 to 1.44; for group effect, sam-
pling time effect, and group effect × sampling time effect,   P   < .001, 
by a two-way repeated measures ANOVA test for tumor growth 
[n = 6 in each group]). In addition, 2MLN-GFP+miTSP-1 tumors 
were smaller than 2MLN-dnT    RII tumors (  Figure 4, E  ; volume 
of 2MLN-GFP+miTSP-1 tumor on day 14 relative to that on day 
0 after starting evaluation = 4.91 and that of 2MLN-dnT    RII 
tumor = 5.65; difference = 0.74, 95% CI =     0.78 to 2.27; the result 
of a two-way repeated measures ANOVA test for the tumor 
growth from days 0 to 14 [n = 6 in each group] for group effect, 
  P   = .010; for sampling time effect,   P   < .001; for group effect × 
sampling time effect,   P   = .025), in agreement with the ﬁ  nding that 
the in vivo expression level of thrombospondin-1 mRNA in the 
2MLN-GFP+miTSP-1 tumors (0.42) was higher than that of the 
2MLN-dnT    RII tumors (0.12; difference = 0.30, 95% CI = 0.12 
to 0.49;   P   = .011) (  Figure 4, F  ). 
  To further elucidate the contribution of enhanced angiogenesis 
to increased tumor growth in the gastric carcinoma model, we 
treated the tumor-bearing mice with sorafenib, a small-molecule 
inhibitor of various tyrosine kinases, including VEGF receptor-2, 
Raf, and platelet-derived growth factor receptor (  30  ,  31  ). Sorafenib 
(40 mg/kg) or a vehicle control was intraperitoneally administered 
into the tumor-bearing mice every day (n = 6 mice per group). 
Treatment with sorafenib strongly suppressed the growth of both 
2MLN-GFP tumors (  Figure 5, A  ; tumor volume in treated mice on 
day 14 relative to that on day 0 after starting evaluation = 0.45 and 
that in untreated mice = 2.73; difference = 2.28, 95% CI = 1.81 to 
2.76; for group effect, sampling time effect, and group effect × 
sampling time effect,   P   < .001, by a two-way repeated measures 
ANOVA test for tumor growth) and 2MLN-dnT    RII tumors 
(  Figure 5, A  ; tumor volume in treated mice on day 14 relative to 
that on day 0 after starting evaluation = 0.79 and that in untreated 
mice = 7.64; difference = 6.85, 95% CI = 4.34 to 9.37; for group 
effect, sampling time effect, and group effect × sampling time effect, 
  P   < .001, by a two-way repeated measures ANOVA test for tumor 
growth). The tumors treated with sorafenib were pale in compari-
son with the untreated tumors, indicating the reduction of tumor 
vasculature and thus hemoglobin. To further conﬁ  rm the effects of 
inhibition of angiogenesis on the tumor growth, an anti-VEGF 
neutralizing antibody (2.5 mg/kg) or a vehicle control was intrap-
eritoneally administered into the tumor-bearing mice twice a week 
(n = 8 mice per group). As with sorafenib treatment, treatment with 
the anti-VEGF neutralizing antibody reduced the volume of both 
2MLN-GFP tumors (  Figure 5, B  ; tumor volume in treated mice on 
day 14 relative to that on day 0 after starting evaluation = 1.89 and 
that in control treated mice = 3.72; difference = 1.83, 95% CI = 0.68 
to 2.98; for group effect,   P   = .003; and for sampling time effect and 
group effect × sampling time effect,   P   < .001, by a two-way repeated 
measures ANOVA test for tumor growth) and 2MLN-dnT    RII 602   Articles | JNCI  Vol. 101, Issue 8  |  April 15, 2009
tumors (  Figure 5, B  ; tumor volume in treated mice on day 14 rela-
tive to that on day 0 after starting evaluation = 1.90 and that in 
control treated mice = 8.05; difference = 6.15, 95% CI = 0.12 to 
12.18; for group effect,   P   = .011; and for sampling time effect and 
group effect × sampling time effect,   P   < .001, by a two-way repeated 
measures ANOVA test for tumor growth).           
    Disruption of TGF-     Signaling in Another Diffuse-Type 
Gastric Carcinoma Cell Line 
  In addition to OCUM-2MLN cells, we also used another diffuse-
type gastric carcinoma cell line, OCUM-12, to investigate the 
effects of disruption of TGF-     signaling. TGF-     induced phos-
phorylation of Smad2 (  Supplementary Figure 2, A  , available 
online) and inhibited the proliferation of OCUM-12 cells in vitro 
(  Supplementary Figure 2, B  , available online), indicating that this 
cell line also responds to TGF-    . To further examine the effects 
of disrupting TGF-     signaling in this cell line, we generated 
OCUM-12 cells expressing GFP or dnT    RII and used them to 
confirm that phosphorylation of Smad2 was attenuated in OCUM-
12-dnT    RII cells (  Supplementary Figure 2, A  , available online). 
We found that TGF-    1  –  induced thrombospondin-1 expression 
was attenuated in the OCUM-12-dnT    RII cells as it was in 
2MLN-dnT    RII cells (  Figure 5, C  ). Moreover, the volume of the 
OCUM-12 tumors expressing dnT    RII was statistically signifi-
cantly larger than that of OCUM-12-GFP tumors (  Figure 5, D  ; 
volume of OCUM-12-dnT    RII tumor on day 14 relative to that 
on day 0 after starting evaluation = 2.19 and that of OCUM-12-
GFP tumor = 1.80; difference = 0.39, 95% CI = 0.014 to 0.772; for 
group effect,   P   = .046; for sampling time effect,   P   < .001; for group 
effect × sampling time effect,   P   = .003, by a two-way repeated 
measures ANOVA test for tumor growth [n = 7 mice in each 
group]), and sorafenib reduced the volume of both OCUM-12-
GFP tumors (volume of treated tumor on day 14 relative to that 
on day 0 after starting evaluation = 1.17 and that of untreated 
tumor = 1.80; difference = 0.63, 95% CI = 0.28 to 0.98; for group 
effect,   P   = .001; and for sampling time effect and group effect × 
sampling time effect,   P   < .001, by a two-way repeated measures 
ANOVA test for tumor growth [n = 7 mice in each group]) and 
OCUM-12-dnT    RII tumors (volume of treated tumor on day 14 
relative to that on day 0 after starting evaluation = 1.36 and that of 
untreated tumor = 2.19; difference = 0.83, 95% CI = 0.51 to 1.15; 
for group effect,   P   < .001; for sampling time effect and group effect 
× sampling time effect,   P   < .001, by a two-way repeated measures 
ANOVA test for tumor growth [n = 7 mice in each group]).   
    Expression of Thrombospondin-1 and Phosphorylated 
Smad2 in Human Gastric Carcinoma Tissues 
  Finally, we examined the status of TGF-     signaling in human 
gastric tumor tissues by use of antibody against phosphorylated 
Smad2 and the level of expression of thrombospondin-1 with anti-
body against thrombospondin-1. Both phosphorylated Smad2 and 
thrombospondin-1 were detected in normal epithelium adjacent to 
tumor (data not shown) and in some diffuse- and intestinal-type 
gastric cancer tissues (  Supplementary Figure 3, A  , available 
online). Immunostaining of 102 human gastric cancer specimens 
revealed that 44 (43%) tumors expressed both phosphorylated 
Smad2 and thrombospondin-1 and that 24 (23%) expressed 
neither (  Supplementary Table 3  , available online). Furthermore, a 
positive association was observed between the expression of 
thrombospondin-1 and of phosphorylated Smad2 (  P   = .002; 
  Supplementary Table 3  , available online). We also found that 
some cancer cells had weaker staining of phosphorylated Smad2 
associated with weaker staining of thrombospondin-1 and that these 
cells were adjacent to cancer cells with strongly positive staining of 
phosphorylated Smad2 and strongly positive thrombospondin-1 
(  Supplementary Figure 3, B  , available online). This observation 
suggested that the level of expression of thrombospondin-1 may be 
associated with the level of TGF-     signaling in each cancer cell, 
which varied even in the same tumor tissue.     
    Discussion 
  We demonstrated in this study that disruption of TGF-     signaling 
in diffuse-type gastric carcinoma models appears to accelerate the 
progression of cancer, as shown by increased growth of the 
2MLN-dnT    RII tumors compared with that of the control 
2MLN-GFP tumors in the subcutaneous and orthotopic trans-
plantation models. Furthermore, microarray analysis of gene 
expression revealed decreased production of thrombospondin-1 in 
the 2MLN-dnT    RII tumors. Overexpression of thrombospondin-1 
suppressed the growth of OCUM-2MLN tumors, but knockdown 
of thrombospondin-1 expression stimulated tumor growth. 
Moreover, we have also demonstrated that regulation of angiogenesis 
by sorafenib or anti-VEGF antibody efficiently prevented the 
growth of tumors in vivo. 
  Systemic administration of TGF-     inhibitors has been shown 
to suppress growth and metastasis of some tumors by acting on 
cancer cells and the tumor microenvironment (  32  ,  33  ). However, 
we found that disruption of TGF-     signaling in diffuse-type gas-
tric carcinoma cells accelerated tumor formation. We found, in 
experiments with a mixture of the wild-type OCUM-2MLN cells 
and OCUM-2MLN cells expressing dnT    RII, that the increased 
growth of 2MLN-dnT    RII tumors appeared to be mainly attrib-
utable to alterations in the tumor microenvironment, not to 
autonomous properties of the cancer cells. The tumor microenvi-
ronment, which has been reported to be important during tumor 
progression (  6  ), contains many structural elements, including 
blood vessels and ﬁ   brotic tissues. Consistently, we found that 
absence of TGF-      –  induced expression of thrombospondin-1, an 
angiogenic inhibitor, is associated with increased growth of dnT  -
  RII tumors in vivo, indicating that increased angiogenesis in the 
dnT    RII-expressing tumors appears to be important in the accel-
erated growth of such tumors. 
  TGF-     binds to T    RII and TGF-     type I receptor      and acti-
vates Smad2 and Smad3, which transduce signals by complexing 
with Smad4. Decreased expression of T    RII, Smad2, and Smad4, 
or loss-of-function mutations in at least one of these genes, has 
been reported in various cancers at advanced stages, including 
breast cancer and colon cancer (  16  ). Decreased expression of 
Smad4 has been observed in many clinical specimens of diffuse-
type gastric carcinoma (  20  ,  34  ). Although mutations in T    RII have 
not been reported in diffuse-type gastric carcinoma, these ﬁ  ndings 
indicate that disruption of TGF-     signaling may accelerate the 
progression of this type of cancer at advanced stages. jnci.oxfordjournals.org    JNCI | Articles 603
  Schwarte-Waldhoff et al. (  29  ) reported that the lack of Smad4 
in an experimental pancreatic cancer model stimulated secretion of 
VEGF, repressed the expression of thrombospondin-1, and led to 
increased angiogenesis and tumor growth. Our microarray data 
revealed that although expression of VEGF was not statistically sig-
niﬁ  cantly altered in the 2MLN-dnT    RII tumors, compared with the 
2MLN-GFP tumors, expression of thrombospondin-1 was reduced. 
Moreover, we found that the expression of thrombospondin-1 was 
induced by TGF-     in the OCUM-2MLN cells but not in the 
2MLN-dnT    RII cells, in agreement with previous reports on the 
induction of thrombospondin-1 by TGF-     in certain cell types, 
including hepatic HuH-7 cells, osteosarcoma MG63 cells, and rat 
tubular epithelial cells (  35  ,  36  ). We obtained similar results with 
another diffuse-type gastric carcinoma cell line, OCUM-12. 
Furthermore, we found that expression of thrombospondin-1 
reduced the growth of 2MLN-dnT    RII tumors in mice and that 
growth of tumors produced from 2MLN-GFP cells in which 
thrombospondin-1 expression had been inhibited was accelerated. 
Moreover, the association that we found between the expression of 
phosphorylated Smad2 and thrombospondin-1 indicated that 
attenuation or loss of TGF-     signaling results in decreased expres-
sion of thrombospondin-1 in human gastric cancer tissues. 
Thrombospondin-1 has been shown to inhibit growth and differ-
entiation of endothelial cells and to induce their apoptosis (  24  ,  25  ). 
Thus, the decreased level of thrombospondin-1 in these tumor 
models appears to accelerate tumor angiogenesis. 
  The importance of tumor angiogenesis in the accelerated 
growth of the 2MLN-dnT    RII tumors was further supported by 
the potent inhibition of tumor growth by treatment with sorafenib, 
regardless of the status of TGF-     signaling in the cancer cells. 
Sorafenib was effective not only in OCUM-2MLN tumors but 
also in OCUM-12 tumors, although the latter were relatively 
resistant to sorafenib’s growth inhibitory effect in vitro 
(A. Komuro, M. R. Kano and K. Miyazono, University of Tokyo, 
M. Yashiro and K. Hirakawa, Osaka City University,  unpublished 
data; the 50% inhibitory concentration [IC  50  ] in OCUM-2MLN 
cells = 1.45   µ  M and in OCUM-12 cells = 8.75   µ  M). Thus, the 
effect of sorafenib on the gastric tumor models in vivo may be 
mostly due to suppression of tumor angiogenesis, although direct 
effects of sorafenib on the gastric carcinoma cells may also contribute 
to its growth inhibitory effect in vivo. In accordance with these 
results, we found that an anti-VEGF neutralizing antibody effec-
tively reduced the growth of OCUM-2MLN tumors. 
  Our study had several limitations. Although we examined the 
growth of diffuse-type gastric carcinoma in subcutaneous and 
orthotopic transplantation models, the experiments were con-
ducted with immunocompromised mice. Immune function may 
affect the growth of diffuse-type gastric carcinoma in human 
patients. Furthermore, we analyzed the growth of primary tumors 
but not the metastasis of tumors. The question of whether TGF-     
signaling regulates metastasis in a cancer cell  –  autonomous fashion 
or in a microenvironment-dependent manner should be explored 
in the future. 
  In conclusion, we have shown that disruption of TGF-     signal-
ing in a mouse model of diffuse-type gastric carcinoma, which may 
be analogous to what occurs during progression of this disease in 
humans, promotes tumorigenesis by accelerating angiogenesis. 
Because the loss of T    RII or Smad4 expression has been reported 
to induce tumor angiogenesis in other types of cancers (  29  ,  37  ), the 
administration of angiogenesis inhibitors, including sorafenib and 
thrombospondin-1 analogues (  38  ), may be useful as a treatment for 
those cancers with disrupted TGF-     signaling pathways.         
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